LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Polliack, Michael"
  2. AU="Ye, Tianai"
  3. AU="Galenson, Walter"
  4. AU="Nisar, Muhammad K"
  5. AU="Keshavarzi, Nahid"
  6. AU="Gabig, Theodore G"
  7. AU="Nixon, Ian J"
  8. AU="Huang Xiaoting"
  9. AU="Colturato, Virgílio Antônio Rensi"
  10. AU="Mahfouz, Amira Y"
  11. AU="Ayyappan, Sabarish"
  12. AU=Wang Kevin L-C
  13. AU="Lukas T. Hirschwald"
  14. AU="Morley-Davies, A"
  15. AU="Felsberg, Gary J"
  16. AU="Bogen, Oliver"
  17. AU="de Portu, Simona"
  18. AU="Janssens, Rick"

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel: Prevention of Post-traumatic stress disorder by Early Psychological Interventions in Israel Following the October 7th Massacre.

    Nacasch, Nitsa / Shoenfeld, Netta / Wul, Ilanit / Polliack, Michael / Weiser, Mark

    The Israel Medical Association journal : IMAJ

    2023  Band 25, Heft 11, Seite(n) 724–728

    Mesh-Begriff(e) Humans ; Stress Disorders, Post-Traumatic/prevention & control ; Stress Disorders, Post-Traumatic/psychology ; Psychosocial Intervention ; Israel/epidemiology ; Cognitive Behavioral Therapy ; Stress, Psychological
    Sprache Englisch
    Erscheinungsdatum 2023-11-18
    Erscheinungsland Israel
    Dokumenttyp Journal Article
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5470: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.

    Dreyer-Alster, Sapir / Menascu, Shay / Mandel, Mathilda / Shirbint, Emanuel / Magalashvili, David / Dolev, Mark / Flechter, Shlomo / Givon, Uri / Guber, Diana / Stern, Yael / Miron, Shmuel / Polliack, Michael / Falb, Rina / Sonis, Polina / Gurevich, Michael / Achiron, Anat

    Journal of the neurological sciences

    2022  Band 434, Seite(n) 120155

    Abstract: Background: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response ... ...

    Abstract Background: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed.
    Objective: Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients.
    Methods: We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response.
    Results: Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administration (IQR 54-84). The frequency of any adverse event was 54.5%, with the most common reported adverse events being fatigue, local pain at the injection site, fever and muscle or joint pain. Transient increase in MS symptoms was reported in 3.8% of patients, none of them requiring treatment. The rate of acute relapses treated with IV steroids was 3.3%. In a sub-group of 55 patients, 20 untreated and 35 treated with vaccination-safe disease-modifying treatments, SARS-CoV-2 IgG levels increased 21-fold (median ± SD 21.6 ± 53.05).
    Conclusions: The third dose of COVID-19-BNT162b2 vaccine proved safe for MS patients, with no increased risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments show significant increase in SARS-CoV-2 IgG levels following the third dose of vaccination.
    Mesh-Begriff(e) Adult ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Humans ; Multiple Sclerosis/drug therapy ; SARS-CoV-2 ; Vaccination/adverse effects
    Chemische Substanzen Antibodies, Viral ; COVID-19 Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Sprache Englisch
    Erscheinungsdatum 2022-01-21
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2022.120155
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 308: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.

    Achiron, Anat / Dolev, Mark / Menascu, Shay / Zohar, Daniela-Noa / Dreyer-Alster, Sapir / Miron, Shmuel / Shirbint, Emanuel / Magalashvili, David / Flechter, Shlomo / Givon, Uri / Guber, Diana / Stern, Yael / Polliack, Michael / Falb, Rina / Gurevich, Michael

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2021  Band 27, Heft 6, Seite(n) 864–870

    Abstract: Background: Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed.: Objective: Characterize safety and occurrence of immediate ... ...

    Abstract Background: Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed.
    Objective: Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients.
    Methods: We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients.
    Results: Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs.
    Conclusion: COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted.
    Mesh-Begriff(e) Adolescent ; Adult ; Age Factors ; Aged ; COVID-19/complications ; COVID-19/epidemiology ; COVID-19 Vaccines/adverse effects ; COVID-19 Vaccines/therapeutic use ; Cohort Studies ; Disability Evaluation ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/complications ; Patient Safety ; Recurrence ; Vaccination ; Young Adult
    Chemische Substanzen COVID-19 Vaccines ; BNT162 vaccine (N38TVC63NU)
    Sprache Englisch
    Erscheinungsdatum 2021-04-15
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585211003476
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4428: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Prolonged exposure therapy for combat- and terror-related posttraumatic stress disorder: a randomized control comparison with treatment as usual.

    Nacasch, Nitzah / Foa, Edna B / Huppert, Jonathan D / Tzur, Dana / Fostick, Leah / Dinstein, Yula / Polliack, Michael / Zohar, Joseph

    The Journal of clinical psychiatry

    2011  Band 72, Heft 9, Seite(n) 1174–1180

    Abstract: Objective: Empirically based studies have demonstrated that prolonged exposure therapy effectively reduces posttraumatic stress disorder (PTSD) symptoms in a vast range of traumas, yet reports of the efficacy of such therapies in combat- and terror- ... ...

    Abstract Objective: Empirically based studies have demonstrated that prolonged exposure therapy effectively reduces posttraumatic stress disorder (PTSD) symptoms in a vast range of traumas, yet reports of the efficacy of such therapies in combat- and terror-related PTSD are scarce. In this article, we examine the efficacy of prolonged exposure therapy in combat- and terror-related PTSD in comparison to treatment as usual (TAU).
    Method: Between July 2002 and October 2005, 30 patients of a trauma unit within a psychiatric outpatient clinic were recruited and randomized into prolonged exposure versus TAU therapies. Patients were diagnosed with chronic PTSD (Mini-International Neuropsychiatric Interview criteria) related to combat- (n = 19) or terror-related (n = 11) trauma. Main outcome measures included symptoms of PTSD and depression, as measured by the PTSD Symptom Scale-Interview Version and the Beck Depression Inventory.
    Results: Posttraumatic stress disorder symptom severity was significantly lower in patients who received prolonged exposure therapy in comparison to patients who received TAU (F(1,24) = 35.3, P < .001). Similar results have emerged in measures of depression and state and trait anxiety. In addition, a significant change from pretreatment to follow-up was found for the prolonged exposure group (F(1,14) = 80.5, P < .0001), but not for the TAU group (F(1,10.3) = 0.6, P = .44).
    Conclusions: Findings indicate that, similar to PTSD related to other types of trauma, prolonged exposure therapy is beneficial in the amelioration of combat- and terror-related PTSD symptoms. In addition, prolonged exposure was superior to TAU in the short- and long-term reduction of PTSD and depression symptoms.
    Trial registration: clinicaltrials.gov Identifier: NCT00229372.
    Mesh-Begriff(e) Adult ; Combat Disorders/therapy ; Female ; Humans ; Implosive Therapy/methods ; Male ; Psychiatric Status Rating Scales ; Stress Disorders, Post-Traumatic/therapy ; Terrorism/psychology ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2011-09
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 716287-x
    ISSN 1555-2101 ; 0160-6689
    ISSN (online) 1555-2101
    ISSN 0160-6689
    DOI 10.4088/JCP.09m05682blu
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 108: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 247: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Effectiveness of sildenafil in treating erectile dysfunction in PTSD patients: a double-blind, placebo-controlled crossover study.

    Orr, Guy / Weiser, Mark / Polliack, Michael / Raviv, Gil / Tadmor, Daphne / Grunhaus, Leon

    Journal of clinical psychopharmacology

    2006  Band 26, Heft 4, Seite(n) 426–430

    Abstract: Objective: Post Traumatic Stress Disorder (PTSD) is known to be associated with Erectile Dysfunction (ED). Sildenafil citrate was shown to be effective treatment for ED among different clinical populations. However, to date, no placebo-controlled trial ... ...

    Abstract Objective: Post Traumatic Stress Disorder (PTSD) is known to be associated with Erectile Dysfunction (ED). Sildenafil citrate was shown to be effective treatment for ED among different clinical populations. However, to date, no placebo-controlled trial has assessed sildenafil's effectiveness for treating ED in PTSD patients. The goal of the present study was to address this question using a double-blind placebo controlled crossover design.
    Methods: A four-week double-blind crossover trial of sildenafil (50 mg up to 100 mg per usage) versus placebo was conducted on 21 outpatients diagnosed with chronic PTSD accompanied by ED. Erectile function was assessed biweekly using the International Inventory of Erectile Function (IIEF). Depressive symptoms, PTSD symptoms and subjective well-being scores were assessed as well.
    Results: Analysis of IIEF scores revealed a main effect of treatment phase (E = 33.361, df =2, P < 0.000). Pairwise comparisons showed that sildenafil IIEF scores (mean = 45.19 +/- 15.05) were significantly higher compared to baseline scores (mean = 20.00 +/- 12.32, P = 0.000) and placebo scores (mean = 33.04 +/- 12.99). Compared to placebo, a significant improvement was also observed during the sildenafil phase in erectile function, orgasmic function and sexual desire. There was no significant change in depression, PTSD symptoms or subjective well-being.
    Conclusion: The results of this study suggest that sildenafil citrate treatment for ED in PTSD patients was accompanied with improvement of ED symptoms and was found to be significantly better than placebo. Nevertheless, this effect should be considered marginal since patients still meet the criteria of ED after treatment. Larger, parallel group studies are warranted.
    Mesh-Begriff(e) Adolescent ; Adult ; Cross-Over Studies ; Double-Blind Method ; Drug Therapy, Combination ; Erectile Dysfunction/complications ; Erectile Dysfunction/drug therapy ; Humans ; Male ; Middle Aged ; Patient Satisfaction ; Penile Erection/drug effects ; Piperazines/administration & dosage ; Piperazines/therapeutic use ; Purines ; Sexuality/drug effects ; Sexuality/physiology ; Sildenafil Citrate ; Stress Disorders, Post-Traumatic/complications ; Stress Disorders, Post-Traumatic/diagnosis ; Stress Disorders, Post-Traumatic/drug therapy ; Sulfones ; Surveys and Questionnaires ; Treatment Outcome
    Chemische Substanzen Piperazines ; Purines ; Sulfones ; Sildenafil Citrate (BW9B0ZE037)
    Sprache Englisch
    Erscheinungsdatum 2006-08
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/01.jcp.0000227701.33999.b3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1664: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.

    Achiron, Anat / Chapman, Joab / Magalashvili, David / Dolev, Mark / Lavie, Mor / Bercovich, Eran / Polliack, Michael / Doniger, Glen M / Stern, Yael / Khilkevich, Olga / Menascu, Shay / Hararai, Gil / Gurevich, Micharel / Barak, Yoram

    PloS one

    2013  Band 8, Heft 8, Seite(n) e71058

    Abstract: Background/aims: Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease ... ...

    Abstract Background/aims: Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years.
    Methods: 1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms.
    Results: Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p=0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p=0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p=0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years.
    Conclusions: The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.
    Mesh-Begriff(e) Adult ; Cluster Analysis ; Cognition ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Models, Statistical ; Multiple Sclerosis/epidemiology ; Multiple Sclerosis/physiopathology ; Time Factors
    Sprache Englisch
    Erscheinungsdatum 2013-08-01
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0071058
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel: Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?

    Amital, Daniella / Fostick, Leah / Polliack, Michael L / Segev, Shlomo / Zohar, Joseph / Rubinow, Alan / Amital, Howard

    Journal of psychosomatic research

    2006  Band 61, Heft 5, Seite(n) 663–669

    Abstract: Objectives: Many features of fibromyalgia syndrome (FMS) resemble those of posttraumatic stress disorder (PTSD). The goal of this study was to investigate the comorbidity of FMS and PTSD in a cohort of men following an intensive, initial, defined ... ...

    Abstract Objectives: Many features of fibromyalgia syndrome (FMS) resemble those of posttraumatic stress disorder (PTSD). The goal of this study was to investigate the comorbidity of FMS and PTSD in a cohort of men following an intensive, initial, defined traumatic event.
    Methods: One hundred twenty-four males (55 patients with PTSD, 20 patients with major depression, and 49 controls) were evaluated for the presence of FMS. The major traumatic events in all PTSD patients were combat-related. Each individual completed questionnaires characterizing his disease, disabilities, and quality of life.
    Results: Forty-nine percent of PTSD patients, compared to 5% of major depression patients and none of normal controls, fulfilled the American College of Rheumatology criteria for FMS (P<.0001). Significant correlations were detected between tender points and measured parameters in the PTSD group.
    Conclusions: In male patients, PTSD is highly associated with FMS. The degree and impact of these disorders are also highly related.
    Mesh-Begriff(e) Adolescent ; Adult ; Combat Disorders/diagnosis ; Combat Disorders/epidemiology ; Combat Disorders/psychology ; Comorbidity ; Cross-Sectional Studies ; Depressive Disorder, Major/diagnosis ; Depressive Disorder, Major/psychology ; Disability Evaluation ; Fibromyalgia/diagnosis ; Fibromyalgia/epidemiology ; Fibromyalgia/psychology ; Humans ; Male ; Middle Aged ; Myofascial Pain Syndromes/diagnosis ; Myofascial Pain Syndromes/epidemiology ; Myofascial Pain Syndromes/psychology ; Quality of Life/psychology ; Sick Role ; Statistics as Topic ; Surveys and Questionnaires
    Sprache Englisch
    Erscheinungsdatum 2006-11
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 80166-5
    ISSN 1879-1360 ; 0022-3999
    ISSN (online) 1879-1360
    ISSN 0022-3999
    DOI 10.1016/j.jpsychores.2006.07.003
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ui I Zs.233: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang